Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib for bone marrow protection in small cell lung cancer chemotherapy
ChiCTR2400086125Phase 4Not yet recruiting
- Sponsor
- Datong Second People's Hospital
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trilaciclib in small cell lung cancer (SCLC), sponsored by Datong Second People's Hospital. Primary endpoints: Incidence of severe neutropenia during treatment cycles and Incidence of agranulocytosis with fever during treatment cycles. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400086125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086125.